Clinical trials · New York, NY
Hematologic Malignancy clinical trials in New York
We’re tracking 33 recruiting hematologic malignancy studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT07006506RecruitingPhase 2
Belumosudil to prevent graft-versus-host disease after transplant
This study tests whether a drug called belumosudil can help prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have had a recent transplant and are at risk for GVHD.
New York, New YorkAges 18 years+ - NCT06208878Enrolling by invitation
Long-term follow-up for CRISPR CAR T therapy recipients
This study follows people who have already received a CRISPR CAR T cell therapy to monitor their long-term health and any side effects. It helps doctors understand how these treatments work over time.
New York, New YorkAges 18 years+ - NCT00920972RecruitingPhase 1/Phase 2
Bone marrow transplant prep for children with non-cancer blood disorders
This early-stage study tests a specific chemotherapy “conditioning” regimen to prepare the body for a bone marrow transplant in children with certain non-cancer blood or immune conditions. It may help the transplant work better, but it also carries risks from the chemotherapy and transplant process.
New York, New YorkAges Up to 20 years - NCT06665100RecruitingPhase 2
Study of PUL-042 for RSV and Related Viruses in Immune-Compromised Patients
This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.
New York, New YorkAges 18 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
New York, New YorkAges 18–66 - NCT07195916RecruitingPhase 1
Testing a new drug for advanced solid tumors and blood cancers
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
New York, New YorkAges 18 years+ - NCT05041309Enrolling by invitation
Long-term follow-up after a Kite gene-cell infusion
This study checks on people long after they received a gene-modified cell infusion in a Kite-sponsored study. It helps researchers understand how treatments work over time and watch for any long-term effects.
New York, New YorkAges Any age - NCT04959903RecruitingPhase 1/Phase 2
SMART101 after T-cell–depleted bone marrow transplant for blood cancers
This early-phase study tests SMART101 given after a T-cell–depleted (T-cell removed) donor bone marrow transplant. It aims to see if the treatment is safe and can help control certain high-risk blood cancers in children and adults.
New York, New YorkAges Any age - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
New York, New YorkAges 18 years+ - NCT05952804RecruitingPhase 2
IVIG to help prevent infections after CAR-T treatment
This Phase 2 study tests whether IVIG (a blood product that helps fight infections) can lower infection risk after you receive CD19 CAR-T therapy. It’s meant to help protect you during the vulnerable period after CAR-T treatment.
New York, New YorkAges 18 years+ - NCT06001788RecruitingPhase 1
Ziftomenib for relapsed or refractory acute myeloid leukemia
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
New York, New YorkAges 18 years+ - NCT06401356RecruitingPhase 3
Long-term study for people already taking pelabresib
This is a follow-up study for people who are already taking the drug pelabresib in another trial and are doing well on it. It allows you to continue receiving pelabresib and monitors your health over a longer period.
New York, New YorkAges 18 years+ - NCT06462365RecruitingPhase 1
Preventing GvHD after stem cell transplant for blood cancers
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
New York, New YorkAges 18 years+ - NCT07220616RecruitingPhase 1/Phase 2
DS3790a for people with blood cancers
This trial tests a new drug called DS3790a for people with certain blood cancers that have not responded well to other treatments. The drug is given for the first time in humans, so researchers are checking its safety and how well it works.
New York, New YorkAges 18 years+ - NCT07572006RecruitingPhase 1
Study of JNJ-95804306 for blood cancers that returned or didn't respond
This trial tests a new drug called JNJ-95804306 for people with certain blood cancers (like acute myeloid leukemia, myelodysplastic syndromes, or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The goal is to see if the drug is safe and if it can help.
New York, New YorkAges 18 years+ - NCT07359859RecruitingPhase 2
Ruxolitinib to prevent GVHD in stem cell transplant
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
New York, New YorkAges 18 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
New York, New YorkAges 1–21 - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
New York, New YorkAges 6 months–25 years - NCT03486873RecruitingPhase 3
Study extension for people on pembrolizumab, testing long-term safety
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
New York, New YorkAges 18 years+ - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
New York, New YorkAges Any age - NCT06938867RecruitingPhase 1/Phase 2
Study of SNIPR001 for resistant gut bacteria before stem cell transplant
This study tests an experimental oral medicine called SNIPR001. It is designed to reduce resistant E. coli bacteria in the gut before your stem cell transplant, possibly lowering the risk of infection.
New York, New YorkAges 18 years+ - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
New York, New YorkAges 18 years+ - NCT04588922RecruitingPhase 1/Phase 2
Study drug SLS009 for high-risk leukemia in adults and teens
This early-phase study tests SLS009 (also called GFH009), a targeted medicine, to treat certain blood cancers—especially high-risk or difficult-to-treat AML. It’s designed to see how the drug works, how safe it is, and what dose may be best for you.
New York, New YorkAges 12 years+ - NCT04515810Recruiting
Mobile app coaching for planning care after serious cancer
This study tests a mobile health app (PACT) to help people with advanced cancer talk and plan for future care. It may help you and a loved one stay engaged in advance care planning (planning what care you want and who should speak for you).
New York, New YorkAges 18 years+
Hear when a new Hematologic Malignancy trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Hematologic Malignancy trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting hematologic malignancy studies listed above.
- Memorial Sloan Kettering Cancer Center · 16 studies
- Weill Cornell Medicine · 5 studies
- John Theurer Cancer Center at Hackensack University Medical Center · 4 studies
- Montefiore Medical Center · 3 studies
- Mount Sinai Health System · 3 studies
- NYU Langone Health · 3 studies
- Rutgers Cancer Institute of New Jersey · 3 studies
- Columbia University Irving Medical Center · 2 studies
What taking part in a hematologic malignancy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting hematologic malignancy studies in New York.
Common questions
- Are there hematologic malignancy clinical trials near New York?
- Yes. We're currently tracking 33 recruiting hematologic malignancy studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a hematologic malignancy study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a hematologic malignancy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New hematologic malignancy studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.